Your shopping cart is currently empty

Dazostinag disodium (TAK-676) is a synthetic novel interferon gene (STING) agonist that triggers STING signaling pathway activation and type I interferon activation. Dazostinag disodium (TAK-676) is also a highly effective immune system modulator with complete resolution and lasting memory of T cell immunity and the ability to promote lasting interferon-dependent anti-tumor immune responses.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 100 μg | $498 | In Stock | In Stock | |
| 500 μg | $998 | In Stock | In Stock | |
| 1 mg | $1,650 | In Stock | In Stock | |
| 5 mg | $3,280 | In Stock | In Stock | |
| 25 mg | $7,630 | In Stock | In Stock |
| Description | Dazostinag disodium (TAK-676) is a synthetic novel interferon gene (STING) agonist that triggers STING signaling pathway activation and type I interferon activation. Dazostinag disodium (TAK-676) is also a highly effective immune system modulator with complete resolution and lasting memory of T cell immunity and the ability to promote lasting interferon-dependent anti-tumor immune responses. |
| Targets&IC50 | CD4+:0.249 μM, natural killer cell:0.271 μM, CD8+:0.216 μM |
| In vitro | METHODS: The ability of TAK-676 to activate the STING pathway was evaluated in human THP1-Dual and mouse CT26 cells treated with dazostinag disodium (TAK-676) (1.1, 3.3, 10 μM, 2 hours). RESULTS Expression of pSTING (S366), pTBK1 (S172), and pIRF3 (S396) was dose-dependently induced in both mouse and human cell lines. [1] |
| In vivo | METHODS: Mice were injected subcutaneously into the right flank with CT26, WT tumor cells, A20 tumor cells, or B16F10 tumor cells, and Dazostinag disodium (TAK-676) (0.3, 1.0, 2.0 mg/kg, intravenously, once every three days, 3 times), and the effects on tumor growth were evaluated by measuring growth rate inhibition (GRI) and tumor regression. RESULTS When Dazostinag disodium (TAK-676) was administered at a dose of 1 mg/kg, BALB/c mice bearing A20 syngeneic tumors showed significant antitumor activity compared to vehicle treatment (GRI 72%, P < 0.001); similar to the A20 tumor model, CT26 tumor-bearing animals treated with 1 mg/kg of Dazostinag disodium (TAK-676) also showed tumor control over vehicle-treated animals; when the dose of Dazostinag disodium (TAK-676) was increased from 1.0 to 2.0 mg/kg, the antitumor activity was significantly increased in both the A20 (GRI=91%, P < 0.001) and CT26 (GRI=132%, P < 0.001) models. [1] |
| Molecular Weight | 754.48 |
| Formula | C21H20F2N8Na2O10P2S2 |
| Cas No. | 2553413-93-5 |
| Smiles | O[C@H]1[C@@]2([C@@H](O[C@@]1(COP([S-])(O[C@@]3([C@@]([H])(COP([S-])(O2)=O)O[C@H]([C@@H]3F)N4C5=NC=NC(N)=C5N=C4)[H])=O)[H])N6C7=C(C(F)=C6)C(N=CN7)=O)[H].[Na+].[Na+] |
| Relative Density. | no data available |
| Storage | store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (331.35 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.